Over the past couple of months, a single plaintiff’s law firm has filed nearly a dozen lawsuits against fiduciaries of defined contribution plans that offer the BlackRock LifePath Index target date funds (“BlackRock Funds”). These cases represent a shift in approach relative to earlier waves of ERISA litigation. While cases in this area have largely targeted investment options that plaintiffs claimed were overpriced “actively managed” funds, the BlackRock Funds are passively managed funds tied to mutual fund indices, and, as a result, carry lower overall expense ratios relative to their actively managed cousins.
What has become colloquially known as “excessive fee” litigation has proven to be both stubbornly persistent and consistently evolving; in fact, that name itself may need to be revisited now that even low-cost indexed funds are in the plaintiffs’ crosshairs. For almost two decades, these “excessive fee” lawsuits have been filed against fiduciaries of defined contribution plans throughout the country, asserting that plan fiduciaries selected investment options which were both overpriced and poorly performing, among other claims. One frequently repeated theory of liability in those cases was that actively managed investment funds did not perform well enough to justify their higher investment management fees (as compared to passively managed funds) and, therefore, should have been removed from a plan’s investment lineup.